ABC Safe Drug Act

The ABC Safe Drug Act (S. 1407), introduced by Senator Cotton, is currently in the early stages of the legislative process, having been read twice and referred to the Senate Committee on Finance on April 10, 2025. This bill seeks to ban federal health care programs, including those operated by HHS, VA, and DoD, from purchasing drugs where active pharmaceutical ingredients (APIs) are manufactured in the People's Republic of China or countries not meeting FDA health and safety standards. The restrictions would phase in, requiring 60% non-Chinese APIs by January 1, 2028, and 100% by January 1, 2030. Waivers are permitted until January 1, 2031. The bill does not appropriate specific funds but creates a structural shift in procurement policy for federal health programs. It also provides a temporary 100% expensing tax incentive for qualified pharmaceutical and medical device manufacturing property placed in service between December 31, 2024, and January 1, 2031. This tax incentive mechanism aims to encourage domestic manufacturing investment rather than direct grants or contracts. The financial impact for companies would stem from either securing federal contracts under the new API requirements or benefiting from the tax expensing for new manufacturing facilities. Structural winners under this bill, should it pass, would be U.S. and allied pharmaceutical manufacturers with existing domestic API production capabilities or those willing to invest in such capabilities. Companies heavily reliant on Chinese APIs would face significant headwinds and require substantial supply chain restructuring to remain eligible for federal contracts. The bill explicitly names the Department of Health and Human Services, the Department of Veterans Affairs, and the Department of Defense as affected agencies, indicating a broad impact on federal drug procurement. The bill also mandates labeling requirements for the country of origin of each active ingredient. Recent market data for major pharmaceutical companies shows a general downward trend over the past 7 days. $PFE is down -3.77%, $MRK is down -1.96%, $JNJ is down -2.43%, $LLY is down -1.13%, and $AMGN is down -3.94%. Over the past 30 days, $MRK is up +1.85%, while $PFE, $JNJ, $LLY, and $AMGN are all down. This market performance is not directly attributable to the ABC Safe Drug Act, given its early legislative stage and the broader market factors influencing these large-cap pharmaceutical companies. The bill's current status as 'Referred to committee' means it has several legislative steps remaining, including committee consideration, potential floor votes in both chambers, and presidential assent. Given its early stage, the bill's ultimate passage and final form are uncertain. However, the sponsorship by Senator Cotton, a senior member, indicates some legislative backing. The bill's focus on supply chain security and domestic manufacturing aligns with broader policy discussions, suggesting potential for movement.